International Journal of Hematology

, Volume 93, Issue 3, pp 281–293 | Cite as

Immunotherapy for EBV-associated malignancies

  • Anna Merlo
  • Riccardo Turrini
  • Riccardo Dolcetti
  • Paola Zanovello
  • Antonio Rosato
Progress in Hematology Cancer immunology

Abstract

Since 1995 to date, more than 250 patients with EBV-related diseases received virus-specific CTL. Cell therapy proved to be safe and effective, and achieved some complete remissions also in patients who failed all previous standard treatments. The first clinical results with EBV-specific CTL were obtained for both prophylaxis and treatment of post-transplant lymphoproliferative disease arising in stem cell transplant or solid organ transplant recipients. Based on such encouraging results, the same approach was then extended to other EBV-related diseases, namely Hodgkin’s lymphoma, nasopharyngeal carcinoma, and chronic active infection. Nowadays, the modification of the CTL generation protocols and the introduction of new specificities into EBV-specific CTL lines by chimeric antigen receptor transfer allow targeting other viral infections and also non-EBV related malignancies. Aim of this review is to summarize clinical results obtained thus far in adoptive cell therapy approaches with EBV-specific CTL. Moreover, by analyzing ongoing clinical trials, we also provide some insights on the potential future of a successful and paradigmatic history.

Keywords

EBV CTL PTLD NPC HL 

References

  1. 1.
    Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ. Epstein–Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol. 2008;18:397–408.PubMedCrossRefGoogle Scholar
  2. 2.
    Li J, Zeng XH, Mo HY, Rolen U, Gao YF, Zhang XS, Chen QY, Zhang L, Zeng MS, Li MZ, Huang WL, Wang XN, Zeng YX, Masucci MG. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One. 2007;2:e1122.PubMedCrossRefGoogle Scholar
  3. 3.
    Gandhi MK, Moll G, Smith C, Dua U, Lambley E, Ramuz O, Gill D, Marlton P, Seymour JF, Khanna R. Galectin-1 mediated suppression of Epstein–Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood. 2007;110:1326–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein–Barr virus. Annu Rev Immunol. 2007;25:587–617.PubMedCrossRefGoogle Scholar
  5. 5.
    Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308.PubMedCrossRefGoogle Scholar
  6. 6.
    Bourgault I, Gomez A, Gomard E, Levy JP. Limiting-dilution analysis of the HLA restriction of anti-Epstein–Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol. 1991;84:501–7.PubMedGoogle Scholar
  7. 7.
    Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O’Reilly RJ. Human Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 SCID/SCID mice. J Exp Med. 1996;183:1215–28.PubMedCrossRefGoogle Scholar
  8. 8.
    Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, Lyerly HK. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery. 1993;114:218–25. (discussion 226).PubMedGoogle Scholar
  9. 9.
    Buchsbaum RJ, Fabry JA, Lieberman J. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in SCID mice. Immunol Lett. 1996;52:145–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Haque T, McAulay KA, Kelly D, Crawford DH. Allogeneic T-cell therapy for Epstein–Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up. Transplantation. 2010;90:93–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr virus-related lymphoproliferation. Lancet. 1995;345:9–13.PubMedCrossRefGoogle Scholar
  13. 13.
    Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549–55.PubMedGoogle Scholar
  16. 16.
    Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005;46:1–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM. Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002;159:123–33.PubMedGoogle Scholar
  18. 18.
    Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, Furione M, Maccario R, Locatelli F. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7:1648–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F. T cell therapy of Epstein–Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis. 2008;40:68–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807–14.PubMedGoogle Scholar
  22. 22.
    Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of solid organ transplant recipients with autologous Epstein–Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M, Vigano M, Fiocchi R, Rossi G, Ginevri F, Gridelli B, Moretta A, Montagna D, Locatelli F, Gerna G, Maccario R. Infusion of autologous Epstein–Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Haque T, Amlot PL, Helling N, Thomas JA, Sweny P, Rolles K, Burroughs AK, Prentice HG, Crawford DH. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol. 1998;160:6204–9.PubMedGoogle Scholar
  25. 25.
    Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA. Treatment of Epstein–Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004;78:755–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Imashuku S, Goto T, Matsumura T, Naya M, Yamori M, Hojo M, Hibi S, Todo S. Unsuccessful CTL transfusion in a case of post-BMT Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant. 1997;20:337–40.PubMedCrossRefGoogle Scholar
  28. 28.
    Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. An Epstein–Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001;97:835–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Immunotherapy for Epstein–Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998;(23):89–93.Google Scholar
  30. 30.
    Khanna R, Bell S, Sherritt M, Galbraith A, Burrows SR, Rafter L, Clarke B, Slaughter R, Falk MC, Douglass J, Williams T, Elliott SL, Moss DJ. Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA. 1999;96:10391–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein–Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005;23:8942–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Sherritt MA, Bharadwaj M, Burrows JM, Morrison LE, Elliott SL, Davis JE, Kear LM, Slaughter RE, Bell SC, Galbraith AJ, Khanna R, Moss DJ. Reconstitution of the latent T-lymphocyte response to Epstein–Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation. 2003;75:1556–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Sun Q, Burton R, Reddy V, Lucas KG. Safety of allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol. 2002;118:799–808.PubMedCrossRefGoogle Scholar
  34. 34.
    De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, Savoldo B. Generation of Epstein–Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009;114(23):4784–91.PubMedCrossRefGoogle Scholar
  35. 35.
    Brewin J, Mancao C, Straathof K, Karlsson H, Samarasinghe S, Amrolia PJ, Pule M. Generation of EBV-specific cytotoxic T-cells that are resistant to calcineurin inhibitors for the treatment of post-transplant lymphoproliferative disease. Blood. 2009;114(23):4792–803.PubMedCrossRefGoogle Scholar
  36. 36.
    O’Reilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen W, Koehne G. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res. 2007;38:237–50.PubMedCrossRefGoogle Scholar
  37. 37.
    Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, Prockop SE, Koehne G, O’Reilly RJ. Successful treatment of Epstein–Barr virus (EBV)-associated post-transplant lymphoma after cord blood transplant using third-party EBV-specific cytotoxic T-lymphocytes. Blood. 2010;116(23):5045–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Hong R, Shen V, Rooney C, Hughes DP, Smith C, Comoli P, Zhang L. Correction of DiGeorge anomaly with EBV-induced lymphoma by transplantation of organ-cultured thymus and Epstein–Barr-specific cytotoxic T lymphocytes. Clin Immunol. 2001;98:54–61.PubMedCrossRefGoogle Scholar
  39. 39.
    Wynn RF, Arkwright PD, Haque T, Gharib MI, Wilkie G, Morton-Jones M, Crawford DH. Treatment of Epstein–Barr virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol. 2005;6:344–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50.PubMedCrossRefGoogle Scholar
  41. 41.
    Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identification of target antigens for the human cytotoxic T cell response to Epstein–Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992;176:157–68.PubMedCrossRefGoogle Scholar
  42. 42.
    Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE, Cytotoxic T. Lymphocyte therapy for Epstein–Barr virus+ Hodgkin’s disease. J Exp Med. 2004;200:1623–33.PubMedCrossRefGoogle Scholar
  43. 43.
    Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Moulec SL, Guigay J, Hirashima M, Guemira F, Adhikary D, Mautner J, Busson P. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein–Barr virus-infected nasopharyngeal carcinoma cells. Blood. 2009;113:1957–66.PubMedCrossRefGoogle Scholar
  44. 44.
    Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA. 2007;104:13134–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Khan G. Epstein–Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin’s lymphoma? Exp Hematol. 2006;34:399–406.PubMedCrossRefGoogle Scholar
  46. 46.
    Marshall NA, Culligan DJ, Tighe J, Johnston PW, Barker RN, Vickers MA. The relationships between Epstein–Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin’s lymphoma. Exp Hematol. 2007;35:596–604.PubMedCrossRefGoogle Scholar
  47. 47.
    Bollard CM, Rossig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, Brenner MK, Heslop HE, Rooney CM. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99:3179–87.PubMedCrossRefGoogle Scholar
  48. 48.
    Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM. A strategy for treatment of Epstein–Barr virus-positive Hodgkin’s disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004;11:81–91.PubMedCrossRefGoogle Scholar
  49. 49.
    Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, Schiavo R, Carminati O, Tagliamacco A, Abbate GF, Locatelli F, Maccario R, Pedrazzoli P. Adoptive transfer of allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol. 2004;15:113–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Chua D, Huang J, Zheng B, Lau SY, Luk W, Kwong DL, Sham JS, Moss D, Yuen KY, Im SW, Ng MH. Adoptive transfer of autologous Epstein–Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 2001;94:73–80.PubMedCrossRefGoogle Scholar
  51. 51.
    Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes. Blood. 2005;105:1898–904.PubMedCrossRefGoogle Scholar
  52. 52.
    Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33:983–90.PubMedCrossRefGoogle Scholar
  53. 53.
    Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE. Immunotherapy for Hodgkin’s disease. Ann Hematol. 2002;81(Suppl 2):S39–42.PubMedGoogle Scholar
  54. 54.
    Roskrow MA, Suzuki N, Gan Y, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM. Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin’s disease. Blood. 1998;91:2925–34.PubMedGoogle Scholar
  55. 55.
    Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006;47:837–42.PubMedCrossRefGoogle Scholar
  56. 56.
    Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004;100:1892–901.PubMedCrossRefGoogle Scholar
  57. 57.
    Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461–70.PubMedCrossRefGoogle Scholar
  58. 58.
    Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009;113:2442–50.PubMedCrossRefGoogle Scholar
  59. 59.
    Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Chan J, Jaffe ES, Ralfkiaer E. Extranodal NK/T cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO classification of tumours. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 204–8.Google Scholar
  61. 61.
    Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, (2002) Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. Autologous Epstein–Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100:4059–66.Google Scholar
  62. 62.
    Hagihara M, Tsuchiya T, Hyodo O, Ueda Y, Tazume K, Masui A, Kanemura A, Yoshiba F, Takashimizu S, Matzusaki S, Kato S, Hotta T. Clinical effects of infusing anti-Epstein–Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection. Int J Hematol. 2003;78:62–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Kuzushima K, Yamamoto M, Kimura H, Ando Y, Kudo T, Tsuge I, Morishima T. Establishment of anti-Epstein–Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol. 1996;103:192–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Cho HI, Hong YS, Lee MA, Kim EK, Yoon SH, Kim CC, Kim TG. Adoptive transfer of Epstein–Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol. 2006;83:66–73.PubMedCrossRefGoogle Scholar
  65. 65.
    Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O’Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M. A novel latent membrane 2 transcript expressed in Epstein–Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood. 2010;116:3695–704.PubMedCrossRefGoogle Scholar
  66. 66.
    Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838–45.PubMedCrossRefGoogle Scholar
  67. 67.
    Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K. Epstein–Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein–Barr virus-carrying natural killer and T cells. Cancer Sci. 2008;99:1633–42.PubMedCrossRefGoogle Scholar
  68. 68.
    Kobayashi H, Nagato T, Takahara M, Sato K, Kimura S, Aoki N, Azumi M, Tateno M, Harabuchi Y, Celis E. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res. 2008;68:901–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Heller KN, Arrey F, Steinherz P, Portlock C, Chadburn A, Kelly K, Munz C. Patients with Epstein–Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer. 2008;123:2824–31.PubMedCrossRefGoogle Scholar
  70. 70.
    Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, Oduor M, Munz C, Rochford R. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer. 2009;124:1721–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Tellam J, Connolly G, Green KJ, Miles JJ, Moss DJ, Burrows SR, Khanna R. Endogenous presentation of CD8+ T cell epitopes from Epstein–Barr virus-encoded nuclear antigen 1. J Exp Med. 2004;199:1421–31.PubMedCrossRefGoogle Scholar
  72. 72.
    Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, Rooney CM, Wang RF. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein–Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004;199:459–70.PubMedCrossRefGoogle Scholar
  73. 73.
    Jones K, Nourse JP, Morrison L, Nguyen-Van D, Moss DJ, Burrows SR, Gandhi MK. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood. 2010;116:2245–52.PubMedCrossRefGoogle Scholar
  74. 74.
    McAulay KA, Haque T, Urquhart G, Bellamy C, Guiretti D, Crawford DH. Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease. J Immunol. 2009;182:3892–901.PubMedCrossRefGoogle Scholar
  75. 75.
    Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol. 2009;21:200–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Merlo A, Turrini R, Bobisse S, Zamarchi R, Alaggio R, Dolcetti R, Mautner J, Zanovello P, Amadori A, Rosato A. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J Immunol. 2010;184(10):5895–902.PubMedCrossRefGoogle Scholar
  77. 77.
    Mautner J, Pich D, Nimmerjahn F, Milosevic S, Adhikary D, Christoph H, Witter K, Bornkamm GW, Hammerschmidt W, Behrends U. Epstein–Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Eur J Immunol. 2004;34:2500–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Adhikary D, Behrends U, Boerschmann H, Pfunder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J. Immunodominance of lytic cycle antigens in Epstein–Barr virus-specific CD4+ T cell preparations for therapy. PLoS One. 2007;2:e583.PubMedCrossRefGoogle Scholar
  79. 79.
    Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. Control of Epstein–Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med. 2006;203:995–1006.PubMedCrossRefGoogle Scholar
  80. 80.
    Long HM, Zuo J, Leese AM, Gudgeon NH, Jia H, Taylor GS, Rickinson AB. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein–Barr virus-transformed B cells. Blood. 2009;114:807–15.PubMedCrossRefGoogle Scholar
  81. 81.
    Amir AL, D’Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R, van der Hoorn MA, Kester MG, Doxiadis II, Falkenburg JH, Claas FH, Heemskerk MH. Allo-HLA reactivity of virus-specific memory T cells is common. Blood. 2010;115:3146–57.PubMedCrossRefGoogle Scholar
  82. 82.
    Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, Rooney CM, Brenner MK, Barrett AJ, Heslop HE. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116(22):4700–2.PubMedCrossRefGoogle Scholar
  83. 83.
    Landais E, Morice A, Long HM, Haigh TA, Charreau B, Bonneville M, Taylor GS, Houssaint E. EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses. J Immunol. 2006;177:1427–33.PubMedGoogle Scholar
  84. 84.
    Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1616–26.PubMedCrossRefGoogle Scholar
  85. 85.
    Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383–93.PubMedCrossRefGoogle Scholar
  86. 86.
    Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008;111:5326–33.PubMedCrossRefGoogle Scholar
  87. 87.
    Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA. 2009;106:17469–74.PubMedCrossRefGoogle Scholar
  88. 88.
    Kaneko S, Mastaglio S, Bondanza A, Ponzoni M, Sanvito F, Aldrighetti L, Radrizzani M, La Seta-Catamancio S, Provasi E, Mondino A, Nagasawa T, Fleischhauer K, Russo V, Traversari C, Ciceri F, Bordignon C, Bonini C. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood. 2009;113:1006–15.PubMedCrossRefGoogle Scholar
  89. 89.
    Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010;22:251–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Vanhoutte VJ, McAulay KA, McCarrell E, Turner M, Crawford DH, Haque T. Cytolytic mechanisms and T-cell receptor Vbeta usage by ex vivo generated Epstein–Barr virus-specific cytotoxic T lymphocytes. Immunology. 2009;127:577–86.PubMedCrossRefGoogle Scholar
  91. 91.
    Wilkie GM, Taylor C, Jones MM, Burns DM, Turner M, Kilpatrick D, Amlot PL, Crawford DH, Haque T. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein–Barr virus-associated diseases. J Immunother. 2004;27:309–16.PubMedCrossRefGoogle Scholar
  92. 92.
    Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalsek D, Jaeger G, Ledderose G, Mautner J, Hammerschmidt W, Schendel DJ, Kolb HJ. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115(14):2960–70.PubMedCrossRefGoogle Scholar
  93. 93.
    Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958–67.PubMedCrossRefGoogle Scholar
  94. 94.
    Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010;115:2695–703.PubMedCrossRefGoogle Scholar
  95. 95.
    Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein–Barr virus infections after haploidentical and matched unrelated stem cell transplant. Blood. 2009;114(19):4283–92.PubMedCrossRefGoogle Scholar
  97. 97.
    Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–70.PubMedCrossRefGoogle Scholar
  98. 98.
    O’Reilly RJ. Epstein–Barr virus sustains tumor killers. Nat Med. 2008;14:1148–50.PubMedCrossRefGoogle Scholar
  99. 99.
    Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, Rosato A. The interplay between Epstein–Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica. 2010;95:1769–77.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Anna Merlo
    • 1
  • Riccardo Turrini
    • 1
  • Riccardo Dolcetti
    • 2
  • Paola Zanovello
    • 1
    • 3
  • Antonio Rosato
    • 1
    • 3
  1. 1.Department of Oncology and Surgical SciencesUniversity of PadovaPaduaItaly
  2. 2.Cancer Bio-Immunotherapy Unit, Department of Medical OncologyCRO, IRCCS, National Cancer InstituteAvianoItaly
  3. 3.Istituto Oncologico Veneto, IOV-IRCCSPaduaItaly

Personalised recommendations